Amiodarone vs Dronedarone Treatments in Patients With Atrial Fibrillation Ron Goldberg | December 7, 2022 At up to 1 year of follow-up, patients taking
The efficacy of dronedarone will need to be further evaluated in comparison trials with established antiarrhythmics for atrial fibrillation
With a regular atrial rate of 300 beats/min, the ventricular rate is usually about 150 beats/min
4-7 The structural changes Catheter ablation of atrial fibrillation (AF) is increasingly being used for treatment of medically refractory, symptomatic AF
Prescribed for Atrial Fibrillation, Atrial Flutter
Aims: Use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is challenging owing to issues with renal clearance, drug accumulation, and increased proarrhythmic risks
Atrial flutter with 1:1 conduction; ventricular tachycardia; may unmask Brugada-type ST elevation; contraindicated with coronary disease double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study
Dronedarone is a benzofuran amiodarone analog which lacks the iodine moiety and contains a methane sulfonyl group that decreases its lipophilicity
Aims: This post hoc analysis of the ATHENA trial (NCT00174785) assessed the effect of dronedarone on the estimated burden of atrial fibrillation (AF)/atrial flutter (AFL) progression to presumed permanent AF/AFL, and regression to sinus rhythm (SR), compared with placebo
Dronedarone is an effective drug for maintaining the sinus rhythm in patients with atrial fibrillation (AF)
Amiodarone has been demonstrated to be the most effective drug in maintaining sinus rhythm and increasing mortality and dronedarone possibly decreasing the incidence of serious adverse events and proarrhythmia
doi: 10
The main adverse drug events in the dronedarone and amiodarone groups were gastrointestinal (6
The DIONYSOS (Efficacy and Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation) trial compared the efficacy and safety of dronedarone (400 mg twice a day [bid]) versus amiodarone (600 mg daily for 28 days, then 200 mg daily thereafter) for at least 6 months for the maintenance of Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone, with two molecular changes, and with a better side effect profile